First National Trust Co Purchases 3,096 Shares of Eli Lilly and Company (NYSE:LLY)

First National Trust Co raised its position in Eli Lilly and Company (NYSE:LLY) by 10.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,035 shares of the company’s stock after purchasing an additional 3,096 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of First National Trust Co’s holdings, making the stock its 20th biggest holding. First National Trust Co’s holdings in Eli Lilly and Company were worth $26,275,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. Principal Financial Group Inc. increased its stake in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the period. GSA Capital Partners LLP acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $606,000. Haverford Trust Co grew its stake in Eli Lilly and Company by 0.9% during the third quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock worth $3,114,000 after purchasing an additional 31 shares during the period. Schrum Private Wealth Management LLC acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $312,000. Finally, Bell Bank grew its stake in Eli Lilly and Company by 1.6% during the third quarter. Bell Bank now owns 1,492 shares of the company’s stock worth $1,322,000 after purchasing an additional 23 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $798.39 on Friday. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The business has a 50-day simple moving average of $830.18 and a 200 day simple moving average of $844.96. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market cap of $757.01 billion, a price-to-earnings ratio of 68.18, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.